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Abstract
The locus coeruleus (LC) is a hindbrain structure that is the major source of norepinephrine (NE)
input to the cortex and other forebrain areas. It is involved in processes of arousal, attention, and
stress. It has been shown that the locus coeruleus norepinephrine system is also involved in the
modulation of feeding. In this experiment, we used triple transgenic mice expressing the hM3Dq
receptor in LC-NE neurons. These mice and littermate controls were overnight fasted then
injected with vehicle or deschloroclozapine (DCZ), which is an inert ligand that solely activates
the designer hM3Dq receptor. The mice were then immediately placed in a feeding assay, where
their food intake was measured at set time points over three hours. We found that activation of
LC-NE neurons via administration of DCZ to the triple transgenic mice suppressed feeding
compared to those injected with vehicle, especially at 3-hours post-injection. Additionally, we
found that LC activation suppressed feeding in female mice more than in male mice. The results
suggest that this dose of DCZ is effective at inducing a change in behavior in mice. The data also
supports the idea that the LC-NE system is involved in the modulation of homeostatic feeding.

Keywords: locus coeruleus, norepinephrine, chemogenetics, feeding
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Introduction
Locus Coeruleus-Norepinephrine System
The locus coeruleus (LC) is a group of neurons in the hindbrain, or brainstem, that
produce the neurotransmitter norepinephrine (NE). These neurons project to various forebrain
and hindbrain areas and receive inputs from many different brain regions (1,2). The LC is a
bilateral structure, meaning it is present in both hemispheres of the brain. Rhombomeres are the
segmental units of the developing hindbrain, each with its own genetic marker (1). The locus
coeruleus is derived from rhombomere 1 cells, and this rhombomere also develops into portions
of the dorsal subcoeruleus and A7 nuclei of the hippocampus (1).
Locus coeruleus neurons have two modes of firing: tonic and phasic. Tonic firing is
characterized by a continual and regular pattern (2). This tonic discharge is implicated in the
modulation of behavioral states of arousal and alertness and increases in response to stress (2,3).
Phasic firing is a short-lived spike in response to relevant sensory stimuli that enables focusing
on a specific task (2). Tonic activation of locus coeruleus neurons through chemogenetic and
optogenetic manipulation has been shown to increase anxiety-like behavior, while inhibition of
the LC-NE neurons decreases this anxiety-like behavior (4). Additionally, the LC suppresses
feeding when optogenetically stimulated and chemogenetically activated by the ligand clozapineN-oxide (CNO) (5,6). Studying the LC-NE system can have implications in treatment for
anxiety, obesity, and disorders related to deficits in sensory processing, such as PTSD, ADHD,
autism, and schizophrenia (7).

Designer Receptors Exclusively Activated by Designer Drugs (DREADDS)
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Designer Receptors Exclusively Activated by Designer Drugs (DREADDs) are used to
selectively activate or inhibit specific types of cells in vivo. G protein-coupled receptors are
mutated to be activated by inert ligands but not their native ligands (8). One widely used
DREADD is the hM3Dq receptor, a Gq-coupled human M3 muscarinic receptor (8). When the
hM3Dq receptor is stimulated, the Gq subunit activates the enzyme phospholipase C (9).
Phospholipase C activates second messengers within the cell and causes calcium to flow into the
cytoplasm (8,9). This Gq-mediated signal transduction pathway leads to excitation of the neuron
(9). The native human muscarinic 3 receptor is activated by acetylcholine (ACh), however this
receptor was modified to be activated by the inert ligand clozapine-N-oxide (CNO) (8). CNO is
extensively used as a designer drug to activate DREADDs, but it metabolizes into the
psychoactive ligand clozapine, which has off-target effects at endogenous receptors (10).
DREADDs and their designer drugs are used to target specific neural circuits and link their
activation to behaviors (9). Advantages of chemogenetic activation include that it is noninvasive
and can activate deep brain structures, while other methods such as optogenetics can be
potentially harmful to the brain tissues and may be spatially restricted (9). Additionally,
pharmacological activation of certain receptors cannot precisely target specific brain regions in
the same manner as chemogenetic manipulation.
To address the problems associated with CNO metabolism into clozapine, a new
DREADD agonist, deschloroclozapine (DCZ), has been synthesized (10). DCZ binds to the
hM3Dq receptor with a 100-fold higher affinity than CNO, so a lower dose of DCZ is needed to
have the same effects as a higher dose of CNO (10). DCZ also has a very low affinity for
endogenous receptors and its metabolites do not have off-target effects either (10). When
systemically administered, DCZ is able to rapidly enter the brain and activate neurons in both
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mice and monkeys (10). DCZ has been used to manipulate behaviors by activating specific
neuron populations in monkeys (10). However, the appropriate doses to initiate a change in
behavior in mice have not been characterized, so in this experiment I will investigate if a 10
µg/kg dose of DCZ is able to sufficiently activate the LC through the hM3Dq receptor.

LC-hM3Dq Mouse Line
In order to express the hM3Dq receptor only in locus coeruleus noradrenergic neurons,
we used a mouse line that uses two recombinase-dependent knock-in alleles (11). En1 is a gene
that defines rhombomere 1, a segment of the developing hindbrain that develops into the
majority of the locus coeruleus and portions of the dorsal subcoeruleus and A7 of the
hippocampus (1). Dopamine-beta hydroxylase (Dbh) is the enzyme responsible for synthesizing
NE from dopamine, so the Dbh gene is expressed in all NE-producing neurons. In the specific
mouse line used for this experiment, the En1 gene drives Cre recombinase expression and the
Dbh gene drives Flp recombinase expression. These genes ensure that Cre and Flp are only
expressed in the noradrenergic neurons of the locus coeruleus. Cre and Flp recombine the alleles
at their specific cut sites, LoxP sites for Cre recombination and FRT sites for Flp recombination,
to result in the expression of hM3Dq fused with the mCherry fluorophore for visualization (11).
When DCZ is injected systemically into these mice, it will only activate the LC-NE neurons, as
these are the only neurons expressing the hM3Dq receptor (Fig. 1).
The RC::FL-hM3Dq allele contains an epitope that localizes the receptor to the soma and
dendrites of neurons (11). This was verified in LC neurons, as mCherry fluorescence was
confined to the soma and dendrites in the LC, indicating that the hM3Dq receptor was localized
to these regions as well (11). The ability of this allele to modulate behavior in vivo when
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activated by CNO was tested (11). As shown previously, optogenetic activation of LC neurons
causes increased anxiety behavior (4). When CNO was administered to the LChM3Dq mice,
anxiety was induced in three assays of anxiety – the elevated plus maze, light dark box, and
open-field test (11). This indicates that the LChM3Dq mouse line can effectively manipulate
behavior when activated through administration of a ligand of the hM3Dq receptor.

Figure 1. DbhFlpo and En1cre drive the expression of the hM3Dq receptor in this triple
transgenic mouse line. Left. LChM3Dq neurons express both DbhFlpo and En1cre. Middle.
Schematic of the RC::FL-hM3Dq allele, depicting how Flp and Cre recombinase recombine
the DNA for proper expression of the hM3Dq receptor. Right. Schematic showing the
portions of the midbrain that express mCherry fused to the hM3Dq receptor, which includes
the LC and portions of the subcoeruleus and A7 of the hippocampus. All other NE-producing
neurons express green fluorescent protein (EGFP). Schematic illustration from Sciolino et al.
2019 (5).

Neural Circuits of Feeding Behavior
The hypothalamus and brainstem are two brain areas that have been implicated in the
regulation of appetite and feeding (12). Destruction of the ventromedial hypothalamus,
hypothalamic paraventricular nucleus, or arcuate nucleus of the hypothalamus results in
overeating and obesity (12). Additionally, activation of the lateral hypothalamus has increased
feeding and hoarding when both hungry and sated (12). On the contrary, feeding is decreased
when neurons between the brainstem and hypothalamus are cut (12).
The neurotransmitter norepinephrine is thought to be involved in the circuits of feeding.
Activation of the a1, b2, and b3-adrenoreceptors decreases eating while activation of the a27

adrenoreceptors increases eating (12). Norepinephrine and other monoamine neurotransmitters
(dopamine and serotonin) are targets of some anti-obesity drugs (12). Locus coeruleus
norepinephrine-producing neurons project to the hypothalamus and specifically those areas
implicated in feeding, including the paraventricular nucleus, arcuate nucleus, and lateral
hypothalamic area (LHA) (1). Therefore, the LC is likely involved in feeding as the source of NE
input into the hypothalamus.
It has been found that optogenetic and chemogenetic activation of LC-NE neurons reduce
food intake (5). When overnight fasted LChM3Dq mice and controls were injected with CNO, the
LChM3Dq mice ate less over a 20-minute period than the control mice (5). Another study also
showed that chemogenetic activation of the hM3Dq receptor in LC neurons by CNO lead to
reduced food intake over a longer 3-hour period (6). In this study, the Cre-responsive hM3Dq
receptor was inserted in an adeno-associated virus (AAV) and injected into mice that express Cre
recombinase in the tyrosine hydroxylase gene (6), which is the rate-limiting enzyme in the
process that synthesizes norepinephrine. Brief and continuous optogenetic stimulation also
confirmed that activation of LC-NE neurons suppresses feeding (5). Flp-dependent AAVs
expressing either ChrimsonR-tdT, a cation channel activated by red-light, or the control
fluorophore tdTomato were injected into the LC of DbhFlpo mice, which express Flp in NE
neurons (5). Photostimulation lead to decreased food intake in the LCChrimsonR mice and not the
LCtdTomato controls, again demonstrating that LC-NE neurons are involved in the suppression of
feeding (5).
Optogenetic activation of a more specific circuit, LC-NE neurons projecting to the LHA,
also suppresses feeding (5). In one experiment, AAVs expressing Cre-dependent
channelrhodopsin-2 (ChR2) or constitutive yellow fluorescent protein (EYFP) were injected into
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the LC of mice expressing the Cre driver in the Dbh gene (5). Channelrhodopsin-2 is a cation
channel that opens in response to blue light and depolarizes the cell (13). ChR2 or EYFP were
expressed in LC-NE neurons, as these neurons expressed Cre and could therefore recombine the
viral DNA to express these proteins. Optogenetic activation of the LC-NE terminals in the LHA
using blue light (465 nm) over a 30-minute period resulted in decreased feeding in fasted mice
expressing ChR2 but not fasted mice expressing EYFP (5). Therefore, the LC-NE to LHA circuit
is involved in feeding behavior.
In this current experiment, fasted LChM3Dq mice and littermate controls were injected with
vehicle or DCZ then their food intake was recorded at set times over a 3-hour period. I predicted
that injection with DCZ would suppress food intake in the triple heterozygous mice of the strain
En1Cre; DbhFlpo; RC::FL-hM3Dq, as was seen in these mice when injected with CNO. This
feeding assay was used to determine an effective dose of DCZ that suppresses feeding to guide
future experiments.

Materials and Methods
Animals
Procedures involving use of mice were approved by the University of Connecticut
Institutional Animal Care and Use Committee. Adult male and female mice between the ages of
3 to 5 months were used for this experiment. Nine triple transgenic En1Cre; DbhFlpo; RC::FLhM3Dq mice and 15 littermate controls were used. One LChM3Dq mouse was excluded from
analyses, as it was a statistical outlier. The triple transgenic mice were generated by crossing
En1Cre mice to double transgenic DbhFlpo; RC::FL-hM3Dq mice7. Mice were group housed and
kept on a reverse l2:12-hour light:dark cycle, with lights off at 9:00 AM. Experiments were
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performed during the active dark period. Mice had access to ad libitum food, except when
overnight fasted the day prior to testing.

Drugs
Deschloroclozapine (DCZ) from Hello Bio (HB8555) was used for this experiment. DCZ
was dissolved in DMSO in a 1 mM stock DCZ. On the day of experiments, the drug was brought
to volume in 0.9% physiological saline to make a dose of 10 µg/kg DCZ. Vehicle was made by
adding saline to <1% DMSO. The body weight of the mice was measured the morning of the
trial, and the compounds were injected at a volume of 0.1 mL/10 g body weight. Drug or vehicle
was injected via intraperitoneal (i.p.) route immediately before behavioral trials.

Food-Intake Test
The food intake test took place in a place preference arena, with one corner containing an
empty food dish and the opposite corner containing a dish filled with standard food. The side in
which the food was placed was counterbalanced for each treatment group. The arena was placed
inside a Med Associates sound attenuating cubicle during testing. Mice were habituated to the
arena and an i.p. saline injection prior to testing in a non-fasted state. Mice were fasted for 24
hours in their own cages a day before testing to motivate feeding. The mice were injected with
DCZ (10 µg/kg, i.p.) or vehicle immediately before testing then given 3 hours to explore the
arena. Food was weighed before the experiment and before each time point. Food was removed
to be weighed at 10 minutes, 30 minutes, 1 hour, 2 hours, and 3 hours into the experiment, then
replaced with new food that was also weighed. Mice were returned to ad libitum food in their

10

group housed cages after testing. All mice were tested with both vehicle and DCZ, with trials
separated by one week.
All trials were recorded using Noldus GigE cameras that were mounted vertically on the
ceiling of the Med Associates cubicles. Noldus Ethovision XT software was used to track the
movement of the mice in the arena. The live video tracking was monitored periodically
throughout the trials to ensure no problems arose with any of the mice.

Statistical Analysis
All statistical analyses were performed using the GraphPad Prism software. All data in
the figures are expressed as mean ± standard error (SEM). Food intake data is presented in grams
(g) or percent change in food intake from vehicle to DCZ. ANOVAs and t-tests were used to
assess differences between groups. All analyses were two-tailed. Tukey’s method was used to
identify any extreme outliers, and it identified one LChM3Dq male mouse that was removed from
all analyses.

Results
LChM3Dq mice and littermate controls were fasted for 24 hours then injected with DCZ
(10 µg/kg, i.p.) or vehicle. They were immediately placed in an arena and food intake was
measured after 10 minutes, 30 minutes, 1 hour, 2 hours, and 3 hours (Fig. 2A). We found that
there was a trend towards a reduction in feeding in LChM3Dq mice receiving DCZ compared to
vehicle, however this result was not statistically significant (Fig. 2B). There was no significant
difference between control mice receiving DCZ or vehicle, indicating that DCZ did not have offtarget effects that impact feeding (Fig. 2B). When the data was expressed as DCZ-induced
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percent change in food intake, we found a trend towards a decrease in feeding in LChM3Dq mice
compared to controls (Fig 2B). There was an average of an 11% decrease in food intake in
LChM3Dq mice compared to approximately a 4% increase in food intake in control mice (Fig. 2B).
At each time point throughout the experiment, there was a trend towards lower food
intake in LChM3Dq mice receiving DCZ compared to those receiving vehicle (Fig. 2C). This
reduction in food intake was most apparent at the 3-hour timepoint (Fig. 2C). There was no
difference in food intake between control mice receiving DCZ or vehicle at any time point (Fig.
2C). Next, we analyzed if there were any sex differences in the suppression of feeding by the LC.
We found a significant difference in percent change in food intake between LChM3Dq male and
female mice (Fig. 2D). Female LChM3Dq mice had nearly a 20% decrease in feeding when the LC
was activated, while male LChM3Dq mice only had about a 2% decrease in feeding (Fig. 2D).
There was no significant difference in food intake between male and female control mice (Fig.
2D). All of our data suggest that chemogenetic activation of LC-NE neurons suppresses feeding.
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Fig 2. Chemogenetic activation of the LC shows a trend towards suppressing food intake,
especially at 3 hours and in female mice. (A) Timeline of the food intake experiment. Mice
were food deprived for 24 hours, injected with DCZ or vehicle, then their food intake was
measured over the next 3 hours. (B) Left. Average food intake in control mice and LChM3Dq
mice receiving vehicle and DCZ. Right. Food intake presented as percent change from vehicle.
Two-tailed, unpaired t-test between LChM3Dq mice and control mice: p=0.16. n=13 control mice
and n=8 LChM3Dq mice. (C) Food intake over the span of 3 hours in control and LChM3Dq mice
receiving DCZ or vehicle. Two-way repeated measures ANOVA: 180 mins, LChM3Dq mice
(p=0.12). (D) Sex differences in DCZ-mediated percent change in food intake. Unpaired, twotailed t-test between male and female LChM3Dq mice: p=0.0065**. n=8 control males, n=7
control females, n=4 LChM3Dq males, n=4 LChM3Dq females.

Discussion
It is known that the locus coeruleus is involved in arousal and alerting animals to salient
stimuli (3,7). Previous studies have also shown that activation of the LC suppresses feeding
(5,6). This current experiment further characterized this using a different designer drug,
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deschloroclozapine. Our approach used a LChM3Dq mouse line to ensure that only the
noradrenergic-producing neurons of the LC would be activated through stimulation of the
hM3Dq receptor. This chemogenetic manipulation was noninvasive and spatially precise.
Our data showed a trend towards decreased feeding when the LC was activated,
especially at the 3-hour mark of the trials. This indicates that this dose of DCZ has long-lasting
effects in the brain, and the amount of time that these effects last should be characterized in
another experiment. Additionally, we found a significant difference in food intake between male
and female LChM3Dq mice. This could indicate a potential sex difference in locus coeruleus
signaling and suppression of feeding. Since this was a small sample size, a future experiment
with a larger sample size is needed to confirm these results. The results suggest that
chemogenetic activation of LC-NE neurons suppresses homeostatic feeding.
Future experiments in the lab will build upon this preliminary experiment, as it was the
first to find a dose of DCZ that is sufficient in activating the LC and initiating a change in
behavior in mice. This dose will be used to chronically activate the LC over the course of four
days. LChM3Dq and control mice will be injected with DCZ (10 µg/kg, i.p.) twice daily and their
food intake and weight will be measured daily and compared to baseline. After characterizing
this chronic dosing, mice at different stages in obesity will be chronically injected with DCZ (10
µg/kg, i.p.) to determine if activating the LC can reduce food intake and cause weight loss in
obese mice. This current experiment and the future experiments could thus have implications in
the treatment of obesity.
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